It was a great pleasure to catch up with Susan Hutchinson (Orange County Migraine & Headache Center, Irvine, CA, USA) to discuss her recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors, for the prevention and treatment of migraine.
The abstract entitled: ‘Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What are the unmet needs in the treatment of migraine in adults with cardiovascular risk factors? (0:13)
- Could you give us a brief overview of the clinical development of small molecule CGRP receptor antagonists for migraine prevention and treatment? (1:01)
- Could you please describe your recent study evaluating the safety and tolerability of rimegepant in adults with CV risk factors? (1:40)
- What were the findings of this study and what are their implications for clinical practice? (3:32)
- What does the future migraine treatment landscape look like? (4:46)
Disclosures: In the past two years, Susan Hutchinson has served as a consultant/advisory board member for Alder/Lundbeck, Allergan/AbbVie, Amgen, Biohaven, Currax, electroCore, Impel, Lilly, Novartis, Teva, Theranica, Upsher-Smith; and is on the speaker’s bureau for AbbVie, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Teva, Theranica and Upsher-Smith.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
